Medical Research Commercialisation Fund (MRCF)

What is the Medical Research Commercialisation Fund?

The Medical Research Commercialisation Fund is an innovative investment collaboration which invests in life science opportunities from its member medical research institutes and their associated hospitals throughout Australia.



The Medical Research Commercialisation Fund is a unique collaboration between CSL, major Australian superannuation funds, the Australian and New Zealand governments, Australian state governments and over 40 leading medical research institutes and research hospitals.

The Medical Research Commercialisation Fund provides its Members with a range of benefits, including:

  • An early-stage fund dedicated to supporting the development and commercialisation of early-stage medical technologies;
  • Access to risk-tolerant investment capital to support the development of promising technologies,
  • Involvement in and exposure to the Investment Review process; and
  • The investors gain access to promising technologies emanating from the Member Institutes.



Established in 2007, investment funding from the Medical Research Commercialisation Fund (MRCF) is available to promising opportunities from its 50 member institutes.

The MRCF’s investors are AustralianSuper, Statewide Super, HESTA, HOSTPLUS and the Australian Government under its IIF program. The MRCF acknowledges support from the State Governments of Victoria, New South Wales, Western Australia, Queensland and South Australia.

Medical Research Commercialisation Fund is managed by Brandon Capital Partners, a life science fund manager, and each member institute nominates a representative to the Investment Review Committee (IRC). The MRCF has received $30 million in funding from superannuation funds and $20 million from the Federal Government’s IIF program.



The Medical Research Commercialisation Fund provides funding of $200,000 to $2 million for any one project, investing up to $1 million on its own, and reserves the second $1 million for further rounds of investment made alongside co-investors. It also provides financial and strategic management assistance.



Eligible applicants include medical research institutes. The Medical Research Commercialisation Fund invests exclusively in opportunities from its member institutes.

Eligible activities include opportunities with milestone-based development programs requiring smaller first round financial commitments to generate further exemplification of the technology.



Application for the Medical Research Commercialisation Fund are open on an ongoing basis.


Current Projects

To date, the MRCF has supported more than 40 promising start-up companies, with over 85 percent of them founded by the MRCF.

Aravax’s mission is to revolutionise the lives of those with peanut allergy by removing the risk of life-threatening reactions to peanuts.

Pathios Therapeutics
Pathios are engaged in a fully-enabled drug discovery program to identify novel small-molecule modulators of GPR65 with expected utility in cancer and certain autoimmune conditions.

George Medicines
George Medicines is developing treatments designed to provide improved clinical outcomes among patients with cardiometabolic diseases such as heart disease, hypertension, and diabetes, which remain the leading causes of premature death and disability worldwide.

PolyActiva is a clinical-stage biotechnology company focused on the development of ocular implants that provide controlled delivery of drugs to both the front and back of the eye.

Certa Therapeutics
Certa Therapeutics novel drugs block a receptor that is a key driver of fibrosis (scarring) of the kidney. Certa is able to use genetic analysis to identify those patients that are most likely to benefit from therapy.

Azura Ophthalmics
Azura Ophthalmics is a clinical-stage biotechnology company headquartered in Tel Aviv-Yafo, Israel. Azura Ophthalmics is developing an innovative portfolio of compounds in combination with a novel drug delivery platform to advance a portfolio of treatments for Meibomian gland dysfunction (MGD), the leading cause of dry eye disease.

Cincera Therapeutics
Cincera Therapeutics (Cincera) is developing range of potent and orally available inhibitors of a key enzymatic target in a lipid metabolism pathway as medicaments for the treatment of NAFLD/NASH and other indications ranging from insulin resistance to CKD and cancer.

EBR Systems
EBR Systems is developing a revolutionary wireless cardiac resynchronisation therapy (CRT) device, WiSE™ to overcome the longstanding issues associated with conventional CRT implants. WiSE™ is a small leadless endocardial implant that is powered by an externally implanted battery transmitter unit. The technology enables clinicians to place the endocardial implant anywhere within the ventricle, based on ideal therapeutic locations.

Ena Therapeutics
Ena Therapeutics is a biotechnology company aiming to transform the treatment and prevention of respiratory infections. The company initial focus is to target respiratory infections in patients with asthma and COPD.

Okogen is a biotechnology company focused on developing therapeutics to help patients with ophthalmic diseases. The lead candidate is OKG-0301, a potent, broad-spectrum antiviral that functions intracellularly to inhibit viral replication and reduce inflammation.

OncoRes Medical
OncoRes Medical is developing an imaging technology that will provide intraoperative information to surgeons to assist with the identification of tumour and healthy tissue.

Q-Sera has developed a gold standard serum tube, with a fast turn-around time that can be manufactured for universal implementation. For many years, the industry has recognized the need for a tube that rapidly produces high quality serum from all blood. Q-Sera’s technology has been developed to meet these needs and uses synthetically produced pro-coagulant proteins called prothrombin activators. The technology was inspired by the venom of some snakes (including the Australian Taipan) that have a potent ability to coagulate the blood.

QUE Oncology
QUE Oncology is a clinical stage company focussed on developing Q-122 for the treatment of hot flashes in cancer survivors undergoing endocrine therapy.

Vaxxas’ proprietary Nanopatch™ vaccine delivery platform provides an optimized, differentiated needle-free vaccine delivery solution that safely and cost effectively amplifies vaccine efficacy.

Denteric is developing vaccines that target the major virulence factors produced by the bacterium Porphyromonas gingivalis (P gingivalis) and related species. In so doing, its primary goal is to provide options to treat and prevent severe periodontal disease and its complications, a condition which affects approximately 1 in 10 people globally.

Longas has developed Morphoseq™, a disruptive technology designed to dramatically improve the performance of industry-standard NGS platforms, by increasing effective read lengths, with benefits in accuracy and cost efficiency. Morphoseq effectively converts short read sequencers into virtual ‘long read’ sequencers, enabling finished-quality genome assemblies with high accuracy, including resolution of difficult-to-assemble genomic regions.

Respirion Pharmaceuticals (Respirion) is developing a novel antibiotic therapy for the treatment of the inherited life-threatening disease, Cystic Fibrosis (CF).

Global Kinetics
Global Kinetics: Corporation provides point of care measurement and reporting of Parkinson’s disease (PD).

MecRx is developing small molecule inhibitors of cMyc, a protein that is deregulated in over 70% of all human cancers. The company has strategic partnerships with Australia’s leading integrated cancer centre, the Peter MacCallum Cancer Centre, and Australia’s premier government research organisation, CSIRO.

OccuRx is a biopharmaceutical company focused on innovative therapeutic strategies for ocular diseases associated with inflammation and fibrosis.

Osprey Medical
Osprey Medical is developing the CINCOR(tm) System for advanced kidney protection during coronary interventions.


More Information

What is the #1 grant for start-ups?

12,000+ companies access the R&D tax incentive per year that yields a CASH REBATE of up to 43.5%.
This might be perfect your start up.
Do you want to know more?

Scroll to Top
R&D Top 10 Consultant Tips

Top 10 Consultant Tips to Maximise the R&D Tax Incentive